{"disease":{"id":"non-infectious-posterior-uveitis","name":"Non-infectious Posterior Uveitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"dexamethasone","indication_name":"Non-infectious Posterior Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03339102","title":"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05414201","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05523765","title":"A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Priovant Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01526889","title":"Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04126850","title":"Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Fakultas Kedokteran Universitas Indonesia","has_results":false},{"nct_id":"NCT00326508","title":"Combination Daclizumab/Denileukin Diftitox to Treat Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}